Oncocyte Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) reported positive coverage for VitaGraft Kidney, expecting commercial revenue in 1H 2024. Cash burn declined to $3.6 million, with $14.2 million in cash, equivalents, and securities as of September 30, 2023. Third quarter 2023 financial results showed a net operating loss of $6.5 million, primarily due to increased R&D expenses.

Positive

• Positive coverage decision for VitaGraft Kidney
• Expected commercial revenue in 1H 2024
• Decline in cash burn to $3.6 million
• Financially well-positioned with $14.2 million in cash, equivalents, and securities

Negative

• Net operating loss of $6.5 million for the third quarter of 2023

-Launching First Products in 1H 2024-

-Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET-

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023.

Third Quarter and Recent Highlights

• VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is expected beginning in 1H 2024.
• Significant new clinical data was presented at the European Society of Organ Transplant Conference demonstrating the VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001).
• Cash burn declined to $3.6 million and is projected to remain below a $5 million quarterly average.
• $14.2 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
• VitaGraft Liver, Oncocyte's second transplant test, continues under review for CMS coverage at MolDX.
  

Josh Riggs, CEO of Oncocyte, commented, “Oncocyte received a positive coverage decision from CMS during the third quarter for the Company's innovative VitaGraft Kidney. This is the test that was recently demonstrated to detect signs of transplant organ rejection a full 10 months earlier than standard of care methods. Going into next year we expect the startup of revenues from the VitaGraft Kidney test and our RUO product, GraftAssure.”  

“Financially, we reduced our cash burn to $3.6 million in the third quarter, the lowest level in several years and a reflection of the sharp reductions in non-revenue related activities that we instituted earlier in the year. Going forward, we expect to maintain this lower level of cash burn and remain below $5 million on a quarterly basis. With $14.2 million in cash, cash equivalents, and marketable securities, a declining cash burn, and multiple products nearing commercialization, we believe that Oncocyte is well positioned for growth in 2024 and the years beyond,” concluded Mr. Riggs.

Third Quarter 2023 Financial Results

Consolidated revenue for the third quarter of 2023 was approximately $0.4 million primarily due to increased revenue from Pharma Services. Cost of revenue was approximately $0.2 million.

Net consolidated operating loss for the three months ended September 30, 2023, was $6.5 million compared to a net consolidated operating loss of $1.7 million for the third quarter of 2022, which included a positive non-cash benefit of $6.1 million for change in fair value of contingent consideration.

Research and Development expense for the third quarter was $2.2 million compared to $1.5 million in the third quarter of 2022, an increase of 48%, driven by continued focused investment in developing manufacturable versions of assays including DetermaIO™, VitaGraft, and DetermaCNI™.

General and Administrative expense for the third quarter was $2.5 million compared to $5.7 million in the year ago period, a decrease of 56%, primarily due to decreased stock-based compensation and personnel expenses.

Sales and Marketing expense for the third quarter was $0.7 million compared to $0.4 million in the comparable period of 2022, an increase of 76%. The increase was driven by a continued ramp in sales, marketing and commercialization activities related to the recent coverage decision and expected upcoming launch of VitaGraft Kidney.

For Oncocyte’s complete financial results for the third quarter ended September 30, 2023, see the Company’s Quarterly Form 10-Q to be filed with the Securities and Exchange Commission on November 9, 2023.

Webcast and Conference Call Information

Oncocyte will host a conference call to discuss the third quarter 2023 financial results prior to market open on Thursday, November 9, 2023 at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time. The live call may be accessed via telephone by dialing toll free (888) 550-5422 for both domestic and international callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at https://investors.oncocyte.com.

About Oncocyte

Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment in order to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy. For more information, visit www.oncocyte.com. 

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, expected revenues and commercial launch of VitaGraft Kidney and GraftAssure in 2024, plans to maintain a cash burn of below $5 million on a quarterly basis, the belief that Oncocyte is well positioned for growth in 2024 and the years beyond, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries’ financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials, changes to regulatory oversight and/or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests. Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

CONTACT:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com

                  -Tables Follow -

ONCOCYTE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
		September 30,				December 31,
			2023				2022
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	13,783			$	19,993
Accounts receivable, net of allowance for credit losses of $178 and $154, respectively			1,882				2,012
Marketable equity securities			441				433
Prepaid expenses and other current assets			672				977
Assets held for sale			139				-
Current assets of discontinuing operations			-				2,121
Total current assets			16,917				25,536
NONCURRENT ASSETS
Right-of-use and financing lease assets, net			1,757				2,088
Machinery and equipment, net, and construction in progress			4,076				8,763
Intangible assets, net			56,617				61,633
Restricted cash			1,700				1,700
Other noncurrent assets			520				371
TOTAL ASSETS		$	81,587			$	100,091
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable		$	1,136			$	1,253
Accrued compensation			1,722				1,771
Accrued royalties			1,116				2,022
Accrued expenses and other current liabilities			826				1,817
Accrued severance from acquisition			2,314				2,314
Accrued liabilities from acquisition			109				109
Right-of-use and financing lease liabilities, current			720				815
Current liabilities of discontinuing operations			90				2,005
Total current liabilities			8,033				12,106
NONCURRENT LIABILITIES
Right-of-use and financing lease liabilities, noncurrent			2,354				2,729
Contingent consideration liabilities			28,715				45,662
TOTAL LIABILITIES			39,102				60,497
Commitments and contingencies
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,217 and $6,091 as of September 30, 2023 and December 31, 2022, respectively			4,923				5,302
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding			-				-
Common stock, no par value, 230,000 shares authorized; 8,261 and 5,932 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively			309,995				294,929
Accumulated other comprehensive income			32				39
Accumulated deficit			(272,465	)			(260,676	)
Total shareholders’ equity			37,562				34,292
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	81,587			$	100,091

ONCOCYTE CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
					Three Months Ended								Nine Months Ended
					September 30,								September 30,
			2023				2022				2023				2022
Net revenue		$	429			$	67			$	1,189			$	684
Cost of revenues			159				314				593				602
Cost of revenues – amortization of acquired intangibles			22				22				66				73
Gross profit			248				(269	)			530				9
Operating expenses:
Research and development			2,185				1,472				6,747				5,923
Sales and marketing			713				405				2,213				798
General and administrative			2,487				5,702				9,430				16,794
Change in fair value of contingent consideration			(435	)			(6,142	)			(16,947	)			(17,157	)
Impairment losses			1,811				-				6,761				-
Loss on disposal and held for sale assets			-				-				1,283				-
Total operating expenses			6,761				1,437				9,487				6,358
Loss from operations			(6,513	)			(1,706	)			(8,957	)			(6,349	)
Other income (expenses):
Interest income (expense), net			117				(14	)			108				(65	)
Unrealized (loss) gain on marketable equity securities			(89	)			(160	)			8				(485	)
Other (expenses) income, net			(4	)			62				(22	)			304
Total other income (expenses)			24				(112	)			94				(246	)
Loss from continuing operations			(6,489	)			(1,818	)			(8,863	)			(6,595	)
Loss from discontinuing operations			-				(7,515	)			(2,926	)			(21,329	)
Net loss		$	(6,489	)		$	(9,333	)		$	(11,789	)		$	(27,924	)
Less: dividends and accretion of Series A redeemable convertible preferred stock			(198	)			(294	)			(739	)			(294	)
Net loss attributable to common stockholders		$	(6,687	)		$	(9,627	)		$	(12,528	)		$	(28,218	)
Net loss from continuing operations per share: basic and diluted		$	(0.79	)		$	(0.31	)		$	(1.19	)		$	(1.22	)
Net loss from discontinuing operations per share: basic and diluted		$	-			$	(1.27	)		$	(0.39	)		$	(3.94	)
Net loss attributable to common stockholders per share: basic and diluted		$	(0.81	)		$	(1.62	)		$	(1.68	)		$	(5.22	)
Weighted average shares outstanding: basic and diluted			8,256				5,931				7,446				5,408

 

 

	Oncocyte Corporation
	Reconciliation of Non-GAAP Financial Measure
	Consolidated Adjusted Loss from Operations
Note: In addition to financial results determined in accordance with U.S. generally accepted accounting principles (GAAP), this press release also includes a non-GAAP financial measure (as defined under SEC Regulation G). We believe the adjusted amounts are more representative of our ongoing performance. The following is a reconciliation of the non-GAAP measure to the most directly comparable GAAP measure:
			For the Three Months Ended
			September 30,				June 30,				September 30,
				2023				2023				2022
			(unaudited)				(unaudited)				(unaudited)
							(In thousands)
	Consolidated GAAP loss from operations		$	(6,513	)		$	(8,294	)		$	(1,706	)
	Stock-based compensation expense			608				834				3,181
	Change in fair value of contingent consideration			(435	)			1,795				(6,142	)
	Severance charge			(7	)			604				1,046
	Depreciation and amortization expense			426				457				1,367
	Impairment losses			1,811				-				-
	Consolidated Non-GAAP loss from operations, as adjusted		$	(4,110	)		$	(4,604	)		$	(2,254	)

 

 

FAQ

What is the ticker symbol of Oncocyte Corporation?

The ticker symbol for Oncocyte Corporation is OCX.

When is the expected commercial revenue for VitaGraft Kidney?

The commercial revenue for VitaGraft Kidney is expected to begin in the first half of 2024.

What was the net operating loss for the third quarter of 2023?

The net consolidated operating loss for the third quarter of 2023 was $6.5 million.

Where can the complete financial results for the third quarter ended September 30, 2023 be found?

The complete financial results can be found in the Company’s Quarterly Form 10-Q to be filed with the Securities and Exchange Commission on November 9, 2023.